Inverness Counsel’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $20.1M | Buy |
233,298
+101,637
| +77% | +$9.07M | 1.12% | 28 |
|
|
2022
Q2 | $12M | Buy |
131,661
+120,471
| +1,077% | +$10.7M | 0.67% | 39 |
|
|
2022
Q1 | $918K | Buy |
11,190
+135
| +1% | +$10.6K | 0.04% | 94 |
|
|
2021
Q4 | $847K | Sell |
11,055
-2,538
| -19% | -$202K | 0.03% | 95 |
|
|
2021
Q3 | $1.02M | Sell |
13,593
-312
| -2% | -$23.7K | 0.04% | 87 |
|
|
2021
Q2 | $1.08M | Sell |
13,905
-3,080
| -18% | -$229K | 0.04% | 86 |
|
|
2021
Q1 | $1.25M | Sell |
16,985
-4,326
| -20% | -$319K | 0.05% | 84 |
|
|
2020
Q4 | $1.66M | Sell |
21,311
-45
| -0.2% | -$3.44K | 0.07% | 72 |
|
|
2020
Q3 | $1.69M | Sell |
21,356
-373
| -2% | -$29.2K | 0.08% | 70 |
|
|
2020
Q2 | $1.6M | Sell |
21,729
-382
| -2% | -$28.8K | 0.08% | 68 |
|
|
2020
Q1 | $1.62M | Buy |
22,111
+209
| +1% | +$16.4K | 0.1% | 63 |
|
|
2019
Q4 | $1.9M | Sell |
21,902
-238
| -1% | -$19.5K | 0.09% | 64 |
|
|
2019
Q3 | $1.78M | Sell |
22,140
-5,135
| -19% | -$412K | 0.09% | 63 |
|
|
2019
Q2 | $2.18M | Sell |
27,275
-1,947
| -7% | -$149K | 0.11% | 61 |
|
|
2019
Q1 | $2.32M | Sell |
29,222
-1,206
| -4% | -$90.2K | 0.13% | 57 |
|
|
2018
Q4 | $2.22M | Sell |
30,428
-1,631
| -5% | -$115K | 0.15% | 57 |
|
|
2018
Q3 | $2.17M | Sell |
32,059
-536
| -2% | -$34.1K | 0.11% | 61 |
|
|
2018
Q2 | $1.89M | Sell |
32,595
-4,418
| -12% | -$249K | 0.11% | 63 |
|
|
2018
Q1 | $1.92M | Sell |
37,013
-20,754
| -36% | -$1.12M | 0.12% | 70 |
|
|
2017
Q4 | $3.1M | Sell |
57,767
-427,584
| -88% | -$23.7M | 0.19% | 54 |
|
|
2017
Q3 | $29.7M | Buy |
485,351
+96,422
| +25% | +$5.85M | 2.09% | 12 |
|
|
2017
Q2 | $23.8M | Sell |
388,929
-31,760
| -8% | -$1.93M | 1.65% | 23 |
|
|
2017
Q1 | $25.3M | Sell |
420,689
-1,001
| -0.2% | -$60.7K | 1.76% | 20 |
|
|
2016
Q4 | $25M | Buy |
421,690
+38,256
| +10% | +$2.24M | 1.89% | 18 |
|
|
2016
Q3 | $22.8M | Sell |
383,434
-12,665
| -3% | -$741K | 1.8% | 23 |
|
|
2016
Q2 | $21.8M | Sell |
396,099
-46,537
| -11% | -$2.48M | 1.69% | 28 |
|
|
2016
Q1 | $22.3M | Buy |
442,636
+25,403
| +6% | +$1.24M | 1.73% | 25 |
|
|
2015
Q4 | $21M | Buy |
417,233
+65,442
| +19% | +$3.3M | 1.59% | 29 |
|
|
2015
Q3 | $16.6M | Sell |
351,791
-9,637
| -3% | -$512K | 1.4% | 30 |
|
|
2015
Q2 | $19.6M | Sell |
361,428
-86,780
| -19% | -$4.87M | 1.42% | 29 |
|
|
2015
Q1 | $24.6M | Buy |
448,208
+60,176
| +16% | +$3.41M | 1.81% | 17 |
|
|
2014
Q4 | $21M | Sell |
388,032
-123,372
| -24% | -$6.87M | 1.62% | 25 |
|
|
2014
Q3 | $28.9M | Sell |
511,404
-12,484
| -2% | -$701K | 2.32% | 12 |
|
|
2014
Q2 | $28.9M | Buy |
523,888
+10,999
| +2% | +$600K | 2.26% | 12 |
|
|
2014
Q1 | $27.8M | Buy |
512,889
+223,313
| +77% | +$11.6M | 2.21% | 14 |
|
|
2013
Q4 | $13.8M | Sell |
289,576
-9,043
| -3% | -$413K | 1.1% | 35 |
|
|
2013
Q3 | $13.6M | Sell |
298,619
-172,609
| -37% | -$7.88M | 1.16% | 34 |
|
|
2013
Q2 | $20.9M | Buy |
+471,228
| New | +$21M | 1.86% | 21 |
|
Other funds holding MRK
Inverness Counsel's MRK Position: Q3 2022 in Review
Inverness Counsel increased its Merck (MRK) stake by 77% in Q3 2022, buying an estimated $9.07M and bringing the position to 233,298 shares worth $20.1M. The position accounts for 1.12% of the portfolio, ranked #28.
Inverness Counsel first reported a position in MRK in Q2 2013 and has held it in 38 quarters since. The position peaked at $29.7M in Q3 2017. 2,990 funds tracked by Wall St. Rank hold MRK as of Q3 2022.
- Inverness Counsel held 233,298 shares of Merck worth $20.1M as of Q3 2022.
- Inverness Counsel bought 101,637 Merck shares in Q3 2022, an estimated $9.07M.
- Merck made up 1.12% of Inverness Counsel's portfolio in Q3 2022, its #28 holding.
- Inverness Counsel first reported a position in Merck in Q2 2013 and has held it in 38 quarters since.
- Inverness Counsel's Merck position peaked at $29.7M in Q3 2017.
- 2,990 funds tracked by Wall St. Rank held Merck as of Q3 2022.
Based on Inverness Counsel's 13F filing for Q3 2022, filed 26 Oct 2022.